Dynavax Technologies (NASDAQ:DVAX) Price Target Raised to $31.00

Dynavax Technologies (NASDAQ:DVAX) had its target price hoisted by HC Wainwright from $29.00 to $31.00 in a research note published on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Dynavax Technologies’ Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.12 EPS, FY2025 earnings at $0.35 EPS and FY2026 earnings at $0.45 EPS.

Dynavax Technologies Trading Down 0.7 %

DVAX opened at $12.39 on Tuesday. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $14.30. The firm has a market capitalization of $1.63 billion, a PE ratio of 95.32 and a beta of 1.34. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The company’s 50-day moving average is $12.78 and its 200 day moving average is $11.66.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Rhumbline Advisers lifted its stake in Dynavax Technologies by 1.8% during the 2nd quarter. Rhumbline Advisers now owns 310,805 shares of the biopharmaceutical company’s stock valued at $3,490,000 after acquiring an additional 5,379 shares in the last quarter. Choreo LLC purchased a new stake in shares of Dynavax Technologies in the second quarter valued at about $363,000. State of New Jersey Common Pension Fund D bought a new position in shares of Dynavax Technologies during the second quarter valued at about $1,811,000. WINTON GROUP Ltd boosted its holdings in Dynavax Technologies by 9.3% during the second quarter. WINTON GROUP Ltd now owns 82,403 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 7,025 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Dynavax Technologies by 2.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock worth $27,830,000 after purchasing an additional 53,600 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.